Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review

ABSTRACT Insomnia is highly comorbid in patients with psychiatric disorders, including depression, bipolar disorder, and substance use disorders, and should be treated as an independent

condition. Dual orexin receptor antagonists (DORAs) have been investigated as a treatment for chronic insomnia. The objective of this systematic review was to examine evidence for two DORAs,

lemborexant and suvorexant, as treatments for insomnia comorbid with a psychiatric disorder. We searched PubMed, Cochrane, and Embase from their inception until January and April 2023, and

included studies examining suvorexant and lemborexant for treating insomnia comorbid with psychiatric disorders. We also manually searched clinical trial registries

(https://clinicaltrials.gov and https://www.umin.ac.jp/ctr). Randomized clinical trials and observational/cohort studies were included. We identified 18 studies from PubMed, Cochrane, and

Embase and three studies from clinicaltrials.gov and UMIN. Of the 21 reports, four were completed/terminated randomized clinical trials, eight were ongoing clinical trials, and nine were

observational studies. We identified evidence for switching from benzodiazepine receptor agonists to a DORA, or using a DORA as add-on therapy and, therefore, discuss this topic as well. Two

studies examined switching to or adding on a DORA in patients being treated with a benzodiazepine receptor agonist. DORAs may be as effective and safe for treating psychiatric comorbid

insomnia (for most psychiatric conditions) as they are for treating primary insomnia. However, the evidence is limited to a few small studies. Further investigation of DORAs for the

treatment of comorbid insomnia in those with coexisting psychiatric conditions is warranted. SIMILAR CONTENT BEING VIEWED BY OTHERS GABAPENTIN AND PREGABALIN IN BIPOLAR DISORDER, ANXIETY

STATES, AND INSOMNIA: SYSTEMATIC REVIEW, META-ANALYSIS, AND RATIONALE Article Open access 24 November 2021 INSOMNIA AND ITS TREATMENTS—TREND ANALYSIS AND PUBLICATION PROFILE OF RANDOMIZED

CLINICAL TRIALS Article Open access 01 November 2024 TREATMENT EFFECT AND SAFETY OF SELTOREXANT AS MONOTHERAPY FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A RANDOMIZED, PLACEBO-CONTROLLED

CLINICAL TRIAL Article Open access 11 December 2024 INTRODUCTION Insomnia has a high comorbidity rate in psychiatric disorders, including depression [1], bipolar disorder [2, 3],

schizophrenia [4,5,6,7,8], generalized anxiety disorder [9, 10], and substance use disorders [11]. The comorbidity of insomnia is related to the severity of psychiatric symptoms

[12,13,14,15]. For instance, patients with depressive symptoms and sleep disturbances may experience more intense and frequent anxiety symptoms, as well as worse cognitive and physical

functioning compared with depressive patients without sleep disturbances [12]. Insomnia symptoms are also related to the prognosis and risk of recurrence of comorbid psychiatric disorders

[16,17,18,19,20]. Patients with depression comorbid with residual sleep disorders have been reported to have a 4.8-fold risk of depression recurrence compared with those without sleep

disorders [16]. Insomnia has also been observed as a prodromal symptom prior to a mood episode recurrence in patients with bipolar disorder [17], and patients with schizophrenia comorbid

with sleep disorders may be at a higher risk of worsening symptoms in response to antipsychotic withdrawal [18]. Some psychotropic drugs have sedative effects, which may help alleviate

insomnia symptoms [21,22,23,24]. Nonetheless, the fact that many patients with comorbid insomnia experience residual insomnia even after remission of the psychiatric disorder [24] leads to

the idea that insomnia is an independent disorder from the comorbid psychiatric disorder. Indeed, the distinction between primary and secondary insomnia has been effaced in the Diagnostic

and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the International Classification of Sleep Disorders, Third Edition. As such, psychiatric symptoms and insomnia should

be treated independently in cases where they appear concomitantly [25, 26]. Current guidelines recommend the use of cognitive behavioral therapy for insomnia (CBT-I) as standard therapy in

the treatment of chronic insomnia [27,28,29]. This is supported by a recent systematic review and meta-analysis, the authors of which also highlighted the importance of the specific

treatment of insomnia in patients with a comorbid mental disorder [30]. However, despite the favorable benefit–risk balance of CBT-I, not all patients with insomnia will derive benefit from

this approach, with reports that responses to CBT-I may be attenuated in insomnia patients with objective short sleep duration compared with those with normal sleep duration [31, 32];

furthermore, access to, or reimbursement for, CBT-I may be limited in some countries. Thus, pharmacotherapy also represents a major component of treatment for insomnia [33] and insomnia

complicated by psychiatric disorders. Benzodiazepine receptor agonists (BZRAs) including benzodiazepines and Z-drugs (i.e., zaleplon, zolpidem, zopiclone, and eszopiclone) [34] have, to

date, comprised the primary pharmaceutical treatment approach for insomnia comorbid with a psychiatric disorder. Several randomized clinical trials (RCTs) investigating Z-drugs for

depression with comorbid insomnia have been reported [35,36,37]. However, long-term use of BZRAs is problematic for various reasons, including dependence and withdrawal symptoms [38].

Recently, dual orexin receptor antagonists (DORAs), which have a different mechanism of action from BZRAs, were developed and launched as a treatment for insomnia. Suvorexant and lemborexant

have been approved in several countries. Orexin is a neuropeptide produced by a limited number of neurons in the lateral hypothalamus that project to a wide range of brain regions,

including monoaminergic and cholinergic neurons. Orexin binds to orexin receptor OX1R and OX2R on these neurons to maintain alertness. DORAs inhibit the effect of orexin by binding both

types of receptors, thus reducing wakefulness. Monoaminergic and cholinergic systems are deeply implicated in the pathogenesis of psychiatric disorders. Nonclinical studies have reported

that antagonism of orexin signaling reduces anxiety-like and substance dependence-like behaviors in rodents [39]. The orexin receptor antagonist seltorexant is a selective antagonist of OX2R

being studied in a phase 3 trial in patients with major depressive disorder with insomnia (NCT04533529) [40]. Although DORAs are effective in insomnia disorder [41, 42], there is limited

evidence for their efficacy in insomnia as a psychiatric comorbidity [43]. In 2020, we published a network meta-analysis comparing the DORAs suvorexant and lemborexant in insomnia [44].

However, the clinical studies assessed in that analysis were limited regarding how many patients with an active psychiatric condition were included. Thus, in the present study, we sought to

review available clinical evidence for DORAs in the context of insomnia as a comorbid condition with a psychiatric disorder. As such, the objective of this review was to evaluate the

evidence on suvorexant and lemborexant as a treatment for insomnia comorbid with a psychiatric disorder, based on RCTs and observational studies. We discuss the usefulness of DORAs for

insomnia comorbid with psychiatric disorders. We also discuss the incidental evidence for switching from a BZRA to a DORA or using a DORA as an add-on to BZRA treatment, as BZRAs have been

widely used for insomnia comorbid with psychiatric disorders. METHODS SEARCH STRATEGY A literature search for this systematic literature review was conducted to identify research studies,

including completed and ongoing RCTs and observational studies, of suvorexant and lemborexant in the treatment of insomnia comorbid with psychiatric disorders. This review was registered and

a review protocol is available at OSF Registries (https://doi.org/10.17605/OSF.IO/SFNUR). The primary search was carried out in January 2023 using the PubMed, Embase, and Cochrane

databases. Search strings followed the following structure: (lemborexant OR suvorexant) AND (various keywords for different mental disorders combined with ‘OR’, based on DSM-5 [25] criteria

and code; see Table S1). Delirium was not included in the scope of psychiatric disorders in this study because the primary objective of many studies in patients with delirium was to

investigate the effect on prevention or treatment of delirium itself, which made it difficult to evaluate the effect of the treatment on insomnia in this population [45]. PubMed and Cochrane

were searched on January 19, 2023, and Embase was searched on January 24, 2023 (Fig S1). To update the search results, we conducted a second search for studies published in these databases

between the date of the first systematic search and April 30, 2023 (Fig. S2). After removing duplicates, “Chapter,” “Conference Abstract,” “Conference Paper,” “Conference Review,”

“Editorial,” “Note,” and “Review” were automatically excluded based on the publication type annotation of the record (Figs. S1 and S2). In addition, trial registries, specifically

clinicaltrials.gov (https://clinicaltrials.gov) and the University Hospital Medical Information Network (UMIN; https://www.umin.ac.jp/ctr), were manually searched for “suvorexant” or

“lemborexant”. STUDY SELECTION For the study selection for analysis in this systematic review, the following inclusion criteria were applied: studies using suvorexant and lemborexant for the

treatment of insomnia comorbid with psychiatric disorders; all or a majority of patients in the study had comorbid psychiatric disorders; and post hoc analyses of insomnia clinical trials

with stratified analysis of patients with comorbid psychiatric disorders. Case series, reviews, meta-analyses, editorials, notes, chapters, and conference presentations were excluded.

Primary screening was conducted based on title and abstract, followed by full-text screening, by at least two independent authors (MK, YK, and TT), and any discrepancies were discussed by

the two authors until an agreement on inclusion/exclusion was reached. We then manually searched and screened results from clinicaltrials.gov and UMIN, in addition to the articles identified

from PubMed, Cochrane, and Embase. RESULTS Based on the first systematic search conducted on the PubMed, Embase, and Cochrane databases, 412 records were obtained after removing duplicates

(Fig. S1). Following exclusion based on title and abstract, 60 full-text articles were assessed for eligibility, and 17 records were finally included. We also included three additional

reports from clinicaltrials.gov and UMIN. After removing duplicates, the second systematic search yielded 41 records that were newly published; one of these records was eligible for

inclusion (Fig. S2). In total, 21 reports were evaluated, including 4 completed/terminated RCTs (Table 1), 9 observational/cohort studies (Table 2), and 8 ongoing clinical trials (Table 3; 1

trial was terminated after the systematic search). RANDOMIZED CLINICAL TRIALS Among the four RCTs identified, there were three placebo-controlled trials with suvorexant, and one open-label

trial in which a benzodiazepine-based sleeping medication was switched to suvorexant or eszopiclone (Table 1). In the placebo-controlled trial of patients with post-traumatic stress disorder

(PTSD)-related insomnia, participants were enrolled if they had insomnia that began or was significantly exacerbated following a DSM-5 Criterion A trauma within 10 years of enrollment (_n_ 

= 37, suvorexant _n_ = 18, placebo _n_ = 19) [46]. Of the enrolled patients, 11.1% in the suvorexant group and 21.1% in the placebo group had maintained the PTSD diagnostic criteria at the

time of enrollment [46]. The Insomnia Severity Index score significantly decreased regardless of treatment group, and there were no differences between treatment groups. Additionally,

polysomnography showed significant increases in total sleep time (TST) and the percentage of rapid eye movement sleep across all subjects, albeit no significant differences were detected

between groups. There was no significant improvement in the Nightmare Severity Scale, which may be partly attributable to low baseline values. Regarding safety, of the 41 patients in the

safety analysis in the study of patients with PTSD-related insomnia [46], one in the suvorexant group discontinued due to moderate somnolence, and another in the suvorexant group developed

mild somnolence, which improved without discontinuation. Neither nightmares nor rapid eye movement-related parasomnias were observed. In a study of patients with insomnia associated with

bipolar disorder who were on treatment (_n_ = 48; _n_ = 23 in the suvorexant group and _n_ = 25 in the placebo group), there were no differences between groups in either subjective TST

(sTST) or actigraphy-measured TST at 1 week [47]. Regarding safety, somnolence was observed as an adverse event (AE) in one patient in the suvorexant group and in one patient in the placebo

group by the first week of treatment; somnolence was also observed in three of the 46 patients in the extended period of suvorexant treatment up to 3 months [47]. There was another study of

suvorexant in patients with insomnia and bipolar disorder, but it was terminated due to COVID-19 (NCT03764683, not shown in Table 1). The fourth, open-label trial with results available was

carried out in patients with major depressive disorder with comorbid insomnia and is discussed below [48]. PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL AND COHORT STUDIES No prospective

cohort studies using DORAs have been reported in patients with comorbid insomnia with any specific psychiatric disorder, but there have been studies reported in patients with comorbid

insomnia with psychiatric disorders more generally (Table 2), including three with suvorexant [49,50,51], and one with lemborexant [52]. In addition, four observational retrospective cohort

studies have been conducted, two with suvorexant [53, 54] and two with lemborexant [55, 56]. One post-marketing study was also reported with suvorexant [57]. Kishi et al. conducted two

open-label, prospective interventional studies with similar protocols, one with suvorexant and one with lemborexant [50, 52]. The 2019 study with suvorexant examined 57 psychiatric patients

with insomnia symptoms and found significant improvements in sTST, subjective time to sleep onset, subjective wake time after falling asleep, and patient sleep satisfaction during the first

week of suvorexant treatment [50]. Similarly, the 2022 study with lemborexant examined 56 psychiatric patients with insomnia symptoms and also found significant improvements in sTST,

subjective time to sleep onset, subjective wake time after falling asleep, and patient sleep satisfaction, with consistent effects regardless of whether the patient had received a prior

baseline dose of sleep medication [50, 52]. Furthermore, subjective visual analog scale scores for severity of mental illness (0 = extremely ill, 10 = no symptoms) improved by 0.53 ± 2.07

and 0.93 ± 2.15 points after 7 days of suvorexant or lemborexant treatment, respectively, with the latter showing a significant improvement compared with baseline [50, 52]. AEs in the

suvorexant study with 57 patients included somnolence (28.8%), fatigue (11.5%), and nightmares (5.8%), and seven discontinuations were caused by AEs (somnolence [_n_ = 3], somnolence and

fatigue [_n_ = 1], fatigue [_n_ = 1], nightmares [_n_ = 1], and vomiting [_n_ = 1]) and inefficacy (_n_ = 2) [50]. In the lemborexant study with 56 patients, fatigue (8.9%) and somnolence

(7.1%) were observed, and discontinuation was caused by an AE in five cases (dizziness [_n_ = 2], agitation [_n_ = 1], nightmares [_n_ = 1], and sleep paralysis [_n_ = 1]) and inefficacy in

one case [52]. Katsuta et al. conducted a retrospective observational study to examine the real-world safety and effectiveness of lemborexant in insomnia comorbid with psychiatric disorders

[56]. In total, 649 patients with different psychiatric disorders were treated with lemborexant for 1 to 8 weeks. Lemborexant response was assessed by the Clinical Global Impression of

Improvement scale, and 64.5% of patients were considered responders based on improvements in insomnia symptoms. The proportion of responders was ≥60% for most types of psychiatric disorders,

including neurodevelopmental disorders (67.7%), bipolar disorders (71.9%), depressive disorders (67.1%), anxiety disorders (64.6%), trauma- and stressor-related disorders (62.5%), and

neurocognitive disorders (62.9%). The safety profile of lemborexant was favorable, with the majority of responders (94.7%) reporting no AEs. The most frequent AEs in the total population

included somnolence (5.1%), headache (2.6%), nightmare (4.9%), and tiredness or malaise (2.6%). Izuhara et al. examined response to suvorexant in patients with insomnia with a comorbid

psychiatric disease, and 20 of 41 patients (49%) in the study population responded to suvorexant with a Pittsburgh Sleep Quality Index (PSQI) improvement of ≥3 points at 4 weeks; of the 38

patients with a psychiatric comorbidity, 19 (50%) responded to suvorexant [49]. In addition, all five patients with depression and 7 of the 13 patients (54%) with schizophrenia and

schizoaffective disorder responded to suvorexant [49]. In another study, Nakamura et al. reported that the global PSQI score significantly decreased from baseline at Week 4 (12.21 ± 0.85 to

9.14 ± 0.79, _p_ < 0.05) [51] as a result of suvorexant treatment in patients with psychosis who also had sleep disturbances (_n_ = 40). The change in comorbid psychiatric symptoms also

improved: anxiety symptoms (Generalized Anxiety Disorder-7 scale) improved from 10.52 ± 1.19 to 5.72 ± 1.10 and depressive symptoms (Patient Health Questionnaire-9) significantly improved

from 13.97 ± 1.44 to 8.79 ± 1.25 (_p_ < 0.01) at week 4. A prospective registry study (post-marketing surveillance) evaluated the efficacy of suvorexant in 2439 patients with insomnia, of

whom 756 had a comorbid psychiatric disorder [57]. The rate of improvement in insomnia symptoms based on physician judgment was 70.6% (534/756) for patients with comorbid psychiatric

disorders and 75.9% (1246/1642) for patients without psychiatric disorders. By type of mental illness, the respective improvement rates were 68.4% and 74.5% for patients with and without

schizophrenia, 72.5% and 74.6% for patients with and without depression, 59.4% and 74.7% for patients with and without manic-depressive illness, and 72.1% and 74.4% for patients with and

without anxiety disorders, with no specific disorder significantly associated based on a multiple regression analysis. In addition, the incidence of adverse drug reactions in patients with

psychiatric disorders was 14.3% (144/1007), which was higher than the incidence of 7.6% (166/2182) in patients without psychiatric disorders. The respective incidences of adverse drug

reactions by psychiatric disorder were 14.1% and 9.6% for patients with or without schizophrenia, 13.8% and 8.9% for patients with or without depression, and 12.8% and 9.5% for patients with

or without anxiety disorders. The major adverse drug reactions in patients with comorbid psychiatric disorders included somnolence, insomnia, dizziness, malaise, and nightmare, which were

also common in patients without psychiatric disorders. It was not mentioned if there were adverse drug reactions specific to patients with psychiatric disorders. Approximately half

(1671/3248; 52.4%) of the patients discontinued treatment for reasons including improvement (17.1%), ineffectiveness (10.9%), lack of effect (4.9%), and AEs (8.0%). A retrospective cohort

study of 150 patients with sleep disorders and comorbid psychiatric disorders presenting to a psychiatric clinic who were treated with lemborexant for 6 months showed significant

improvements in total Athens Insomnia Scale score (_p_ < 0.01), with 21 patients achieving remission and discontinuing the treatment [55]. Other reasons for discontinuation included lack

of effect (_n_ = 4), somnolence (_n_ = 5), fatigue (_n_ = 1), and nightmares (_n_ = 1). SWITCHING FROM BENZODIAZEPINES TO DORA We found a few studies that investigated outcomes for patients

switching from benzodiazepines to a DORA. In an open-label RCT of patients with insomnia with comorbid major depressive disorder (_n_ = 18) who did not respond adequately to benzodiazepines

and then switched to either suvorexant (_n_ = 9) or eszopiclone (_n_ = 9), the Insomnia Severity Index score declined after switching similarly in both groups, and there were no significant

differences between the groups (Table 1) [48]. In a retrospective cohort study of patients with insomnia (_n_ = 228) taking benzodiazepines, the retention rates of suvorexant treatment were

confirmed for both a “Switch” group who substituted all or a part of benzodiazepines with suvorexant and an “Add-on” group who did not reduce the benzodiazepine dose at suvorexant initiation

(Table 2) [58]. Among all study participants, 73.2% had comorbid psychiatric disorders (depression 25.9%, bipolar disorder 19.7%, schizophrenia 11.4%). The discontinuation rate was 24.4% in

the Switch group and 45.0% in the Add-on group. The main reasons for discontinuation in the Switch group were inadequate efficacy (62.1%), intolerance (31.0%), and somnolence (17.2%), while

in the Add-on group, more patients discontinued due to intolerance (49.0%). Furthermore, the combined benzodiazepine dose (in diazepam equivalent values) in the Switch group decreased from

8.5 ± 5.8 mg to 3.9 ± 4.9 mg after 1 month, and 46.2% of the patients successfully withdrew from the benzodiazepines. Another retrospective cohort study of patients with insomnia and

comorbid psychiatric disorders included 90 patients who took benzodiazepines and 57 patients who took Z-drugs before the initiation of lemborexant treatment [56]. Among those, 58.9% of those

who switched benzodiazepine and 63.2% of those who switched Z-drug were considered responders who showed improvements in insomnia symptoms based on the Clinical Global Impression

improvement scale. DISCUSSION In this systematic review, we comprehensively extracted and reviewed clinical trials of suvorexant and lemborexant for patients with insomnia comorbid with

psychiatric disorders. Most of the studies identified were cohort trials investigating patients treated with DORAs, with limited available studies of placebo-controlled RCTs. The RCTs

completed to date showed no difference in efficacy between DORAs and placebo, possibly due to the robust placebo effect and the sample size [46]. The differences from baseline in the active

treatment group were similar to those observed in the phase 3 studies on primary insomnia; there is no evidence to suggest that the efficacy of DORAs for patients with comorbid psychiatric

disorders is less than that for patients with primary insomnia. Seven additional RCTs are currently ongoing with suvorexant and lemborexant (Table 3) [59,60,61,62,63,64,65], three of which

involve insomnia associated with substance use disorders (NCT05458609 [59], NCT03897062 [60], and NCT04287062 [61]). The role of orexin in the formation of dependence on substances and

substance use has been suggested in nonclinical and clinical studies [66]. The results of both prospective and retrospective observational cohort studies also showed that treatment with

either suvorexant or lemborexant was associated with a significantly improved sleep index in patients with insomnia who had a comorbid psychiatric disorder, without worsening the comorbid

psychiatric disorders. Regarding safety, no new AEs were observed in patients with comorbid psychiatric disorders compared with traditional clinical trials, which reported similar safety

findings in patients with primary insomnias. Regarding DORA discontinuation rates, in the suvorexant cohort study (_n_ = 228), the discontinuation rates were 45.0% and 24.4% in the Add-on

and Switch groups, respectively [58]. Across the two groups, 36 discontinuations were due to inefficacy, and the remainder were due to AEs. In the lemborexant cohort study (_n_ = 150), the

discontinuation rate for patients who started lemborexant and who switched from a benzodiazepine hypnotic was 22.6% (34/150), with the most common reason for discontinuation being “Improved”

(_n_ = 21) [55]. One reason for the discrepancy between these two studies is the difference in the frequency of prior hypnotic medication. Another reason might be that the approved dose of

suvorexant in Japan is available only at 20 mg (15 mg for elderly patients), whereas lemborexant is approved in 5-mg and 10-mg doses, meaning that the option to increase the dose of

lemborexant may have influenced the improved continuation rate. The efficacy and safety findings of the studies included in this review suggest that suvorexant or lemborexant may be

recommended as an effective option for managing insomnia in those with comorbid psychiatric conditions. EFFECTS OF TREATMENT OF INSOMNIA WITH DORAS IN PSYCHIATRIC DISORDERS That several

cohort studies have demonstrated significant baseline improvements in comorbid psychiatric disorders along with improvements in insomnia in patients treated with DORAs indicates that

treatment does not adversely affect the comorbid psychiatric disorder [51, 52]. Although the present study does not allow us to conclude whether DORAs ameliorate symptoms of the psychiatric

disorders, administration of DORAs may benefit patients with psychiatric disorders associated with insomnia for a couple of reasons. First, DORA administration increased sleep satisfaction

and reduced the burden on patients with mental illness, which may have had a spillover effect in improving mental illness severity. This is supported by two prospective cohort studies of

lemborexant and suvorexant conducted with the same study design, which found that cohorts with greater changes in sleep satisfaction also experienced greater improvements in mental illness

severity [50, 52]. Second, as suggested in a recent systematic review, orexin dysregulation may potentially be involved in psychiatric disorders themselves [67]. In fact, administration of

orexin receptor antagonists alleviates depression, anxiety-like behaviors, and substance dependence in animal models [39, 68]. Several placebo-controlled RCTs are being conducted to examine

these non-insomnia effects of DORAs [69,70,71,72]. In a phase 3 clinical trial of suvorexant, increased suicidal ideation was observed at the higher dose (30/40 mg) [42, 73]; however,

suicide risk with lower doses of suvorexant is low [42, 55], no increased suicide risk has been observed with lemborexant, and the risk with both drugs is manageable by monitoring patients

for signs of worsening depression or suicidal thoughts. In fact, as shown in this systematic literature review, evidence of safety in patients with depression with comorbid insomnia is

accumulating. In a prospective crossover study of suvorexant, in which 15.6% (_n_ = 508/3248) of the study population had depression, only one case of worsening depression was observed as an

adverse effect of treatment [57]. In addition, two prospective interventional studies of suvorexant and lemborexant by Kishi et al. included 49.1% (_n_ = 28) and 21.4% (_n_ = 12) of

patients with depression and major depression, respectively, at baseline, and did not observe any treatment-related worsening of depression [50, 52]. Therefore, DORAs appear safe for

patients with insomnia as a comorbid condition of psychiatric conditions, as no deterioration of comorbid depression was observed with DORA treatment. Nonetheless, since the sample sizes in

the studies evaluated were generally small, larger RCTs are needed to acquire robust results. SAFETY OF DORAS IN PSYCHIATRIC DISORDERS In the suvorexant post-marketing study, the incidence

of adverse drug reactions (ADRs) was higher in those with psychiatric disorders than in those without. This trend was independent of the type of comorbid psychiatric disorder [57]. Frequent

ADRs included somnolence, insomnia, headache, and dizziness, which have been observed in previous clinical trials, suggesting that sleep medication-related ADRs may be more likely to occur

in patients with psychiatric comorbidities. The nature of comorbid psychiatric disorders may be a contributing factor in the increasing frequency of ADRs. Furthermore, many patients were

prescribed psychotropic medications, and the concomitant use of a drug that affects the nervous system may have caused nervous system ADRs. Twenty of the 144 patients with psychiatric

disorders had AEs of insomnia [57], and it is possible that the drug was not sufficiently effective to treat insomnia in these patients. Therefore, careful administration and patient

monitoring are needed. Although drug treatment of insomnia should be short term, patients with comorbid psychiatric disorders often have recurrent psychiatric illnesses and treatment of

insomnia can be long term. The studies reviewed here had a ≤ 6-month duration, and the safety of DORAs over a longer period of time is unknown in this population. On the one hand, dependence

and tolerance are concerns with long-term use of sleeping medications. In a prescribing analysis of BZRAs in Japan, the dose increased with the length of treatment period [73]. On the other

hand, there is no clear evidence of dependence or tolerance with DORAs. In a phase 3 clinical trial in patients with insomnia, no withdrawal symptoms or rebound insomnia were observed after

withdrawal of the drug after up to 12 months of medication [74, 75]. Further studies are required to evaluate long-term safety in patients with comorbid psychiatric disorders. Of note,

obstructive sleep apnea (OSA) may contribute to the development of chronic insomnia, so patients should also be assessed for the possibility of OSA. It has also been reported that the

prevalence of OSA is higher in patients with psychiatric disorders [76], making this particularly important in this patient group. SHOULD INSOMNIA COMORBID WITH PSYCHIATRIC DISORDERS BE

TREATED AS A DISORDER INDEPENDENT OF PSYCHIATRIC SYMPTOMS? Recently, the term “secondary insomnia” has been eliminated from the DSM-5 and other guidelines as insomnia can persist even after

the primary symptoms of psychiatric disorders have been resolved. Insomnia is now regarded as a distinct disorder independent of psychiatric disorders. Based on this concept, treatment with

insomnia medications should be considered for insomnia symptoms that are not sufficiently improved by psychiatric medications. Insomnia associated with psychiatric disorders is often treated

with drugs that have a strong sedative effect on the underlying disorder, which can effectively address hyperarousal and sleep disorders that commonly occur in the acute phase of a

psychiatric condition [22]. However, they are not approved for insomnia and have not been rigorously studied for insomnia comorbid with psychiatric disorders. Furthermore, the use of

sedative medications for psychiatric disorders presents several challenges. First, the effects of psychiatric medications on sleep can result in excessive sedation during the day, leading to

reduced daytime functioning and quality of life. This is particularly true during the maintenance phase of treatment when symptoms of the primary illness have abated and the sedative

effects of medication initiated during the acute phase have become more prominent. Even taking medication before bedtime may impair daytime functioning if the clinical effects persist beyond

the desired duration. In addition, sedating psychiatric medications may be associated with specific adverse effects. For example, although quetiapine, clozapine, and olanzapine can

influence sleep by their antihistamine effects [21], they are associated with weight gain and elevated blood lipids [77,78,79,80]. These safety issues may prevent the administration of

sufficient doses of psychiatric medications to improve insomnia symptoms, further preventing the adequate management of insomnia. According to the findings of this review, suvorexant and

lemborexant showed no clear adverse effects on psychiatric disorders comorbid with insomnia. In addition, DORAs are expected to have a low dependence due to their differential mechanism of

action from older benzodiazepine hypnotics, making them a promising treatment option for insomnia comorbid with psychiatric disorders. Finally, the use of DORAs in the treatment of chronic

insomnia has already been discussed in other reviews [44]. Briefly, based on a network meta-analysis of phase 3 trials, the recommended strategy is to begin with 5 mg of lemborexant and

increase to 10 mg if efficacy is insufficient. The network meta-analysis showed that lemborexant 5 mg is superior to suvorexant 15 or 20 mg at 1 week of treatment in subjective time to sleep

onset, and 10-mg lemborexant is more effective than 5-mg lemborexant in sTST and subjective wake time after falling asleep, though 10-mg lemborexant carries an increased risk of

discontinuation due to AEs and somnolence. In clinical trials, somnolence was the most common AE observed in subjects treated with suvorexant or lemborexant [41, 42, 81]. Although

infrequent, nightmares, abnormal dreams, and sleep paralysis have also been reported with DORA treatment [41, 42, 78]. Because most of these events were mild-to-moderate in severity and

rarely resulted in treatment discontinuation, it is advisable to inform patients in advance that these AEs may occur as a result of DORA therapy. As data emerge on DORA use in the context of

psychiatric conditions, we expect to learn more about specific AE scenarios to consider when treating this patient population with this class of drugs. SWITCHING FROM BENZODIAZEPINES TO

DORAS In this review, we found a few small-scale studies confirming that suvorexant and lemborexant are efficacious and safe after switching from a BZRA or when used as an add-on therapy to

a BZRA [48, 58]. For patients who have had problems with long-term BZRA use, including dependence, tolerance, cognitive impairment, and falls, switching to a DORA can be considered. The

method of how to initiate DORA treatment in patients receiving BZRAs should take into account the abuse liability of the BZRA, the history and dose of the BZRA, and the user’s willingness to

switch. Direct switching may be possible in patients using drugs with low abuse liability who are dissatisfied with the drug and willing to switch [82, 83]. However, for patients using a

BZRA with high abuse liability, long-term users, and high-dose users, starting a DORA as an add-on while gradually tapering the previous drug may be advisable, as demonstrated in the study

by Hatano et al. [58]. Because insomnia is exacerbated by anxiety, it is important to achieve sleep continuity through a combination of tapering and add-on therapy to effectively treat

insomnia and increase patient confidence in their ability to sleep. In general, the available data on switching indicate that patients with insomnia and comorbid psychiatric symptoms may

benefit from switching to, or adding on, a DORA if BZRA treatment does not sufficiently manage symptoms. LIMITATIONS Because no large, randomized, double-blind trials were included in this

systematic review, it was not possible to verify efficacy compared with placebo in terms of sleep improvement. Similarly, because of the limited number and short-term nature of studies

identified, there were insufficient data available to draw conclusions on improvements in sleep for each comorbid psychiatric disorder, the impact of DORA treatment on the symptoms of the

psychiatric disorders, or the long-term effects of such treatment. Moreover, results that were posted only on clinicaltrials.gov (e.g., NCT02527564 [47]) and not published in a peer-reviewed

journal should be interpreted with caution. To elucidate these issues, larger-scale prospective observational studies are needed. In the treatment of insomnia comorbid with psychiatric

disorders, it is also necessary to examine the compatibility of DORAs with drugs for psychiatric disorders, which will be verified through retrospective studies. CONCLUSION In patients with

psychiatric disorders, sleep deprivation is a significant burden, regardless of the type of psychiatric disorder. CBT-I is the standard treatment option and—if CBT-I cannot be used or is

ineffective—a variety of drug treatment options are available. DORAs, with their unique mechanism of action, may be reasonable choices. Although there is a lack of Level 1 evidence on

efficacy in patients with comorbid psychiatric disorders, evidence suggests that DORAs have a tolerable safety profile. Further studies—particularly those that are long term—are needed, and

the results of the ongoing RCTs are eagerly anticipated. DATA AVAILABILITY All data analyzed for this review are available in this document and supporting information. REFERENCES * Geoffroy

PA, Hoertel N, Etain B, Bellivier F, Delorme R, Limosin F, et al. Insomnia and hypersomnia in major depressive episode: Prevalence, sociodemographic characteristics and psychiatric

comorbidity in a population-based study. J Affect Disord 2018;226:132–41. Article  PubMed  Google Scholar  * Laskemoen JF, Simonsen C, Büchmann C, Barrett EA, Bjella T, Lagerberg TV, et al.

Sleep disturbances in schizophrenia spectrum and bipolar disorders - a transdiagnostic perspective. Compr Psychiatry. 2019;91:6–12. Article  PubMed  Google Scholar  * Steinan MK, Scott J,

Lagerberg TV, Melle I, Andreassen OA, Vaaler AE, et al. Sleep problems in bipolar disorders: more than just insomnia. Acta Psychiatr Scand 2016;133:368–77. Article  PubMed  CAS  Google

Scholar  * Cohrs S. Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics. CNS Drugs. 2008;22:939–62. Article  PubMed  CAS  Google Scholar  * Batalla-Martín

D, Belzunegui-Eraso A, Miralles Garijo E, Martínez Martín E, Romaní Garcia R, Heras JSM, et al. Insomnia in schizophrenia patients: prevalence and quality of life. Int J Environ Res Public

Health. 2020;17:1350. Article  PubMed  PubMed Central  Google Scholar  * Xiang YT, Weng YZ, Leung CM, Tang WK, Lai KYC, Ungvari GS. Prevalence and correlates of insomnia and its impact on

quality of life in Chinese schizophrenia patients. Sleep. 2009;32:105–9. PubMed  PubMed Central  Google Scholar  * Hou CL, Li Y, Cai MY, Ma XR, Zang Y, Jia FJ, et al. Prevalence of insomnia

and clinical and quality of life correlates in Chinese patients with schizophrenia treated in primary care. Perspect Psychiatr Care. 2017;53:80–6. Article  PubMed  Google Scholar  * Palmese

LB, DeGeorge PC, Ratliff JC, Srihari VH, Wexler BE, Krystal AD, et al. Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophr Res. 2011;133:238–43.

Article  PubMed  PubMed Central  Google Scholar  * Navarrete FF, Páramo MP, Ordoño JF, Gómez VL. Prevalence of insomnia and associated factors in outpatients with generalized anxiety

disorder treated in psychiatric clinics. Behav Sleep Med. 2017;15:491–501. Article  Google Scholar  * Monti JM, Monti D. Sleep disturbance in generalized anxiety disorder and its treatment.

Sleep Med Rev. 2000;4:263–76. Article  PubMed  Google Scholar  * Provencher T, Lemyre A, Vallières A, Bastien CH. Insomnia in personality disorders and substance use disorders. Curr Opin

Psychol. 2020;34:72–6. Article  PubMed  Google Scholar  * Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, et al. Relationship between sleep disturbance and depression,

anxiety, and functioning in college students. Depress Anxiety. 2013;30:873–80. Article  PubMed  Google Scholar  * Gruber J, Harvey AG, Wang PW, Brooks JO 3rd, Thase ME, et al. Sleep

functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Affect Disord. 2009;114:41–9.

Article  PubMed  Google Scholar  * Benson KL. Sleep in schizophrenia: pathology and treatment. Sleep Med Clin. 2015;10:49–55. Article  PubMed  Google Scholar  * Meaklim H, Saunders WJ, Byrne

ML, Junge MF, Varma P, Finck WA, et al. Insomnia is a key risk factor for persistent anxiety and depressive symptoms: a 12-month longitudinal cohort study during the COVID-19 pandemic. J

Affect Disord. 2023;322:52–62. Article  PubMed  CAS  Google Scholar  * Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in

community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165:1543–50. Article  PubMed  PubMed Central  Google Scholar  * Van Meter AR, Burke C, Youngstrom EA, Faedda GL,

Correll CU. The bipolar prodrome: meta-analysis of symptom prevalence prior to initial or recurrent mood episodes. J Am Acad Child Adolesc Psychiatry. 2016;55:543–55. Article  PubMed  Google

Scholar  * Chemerinski E, Ho BC, Flaum M, Arndt S, Fleming F, Andreasen NC. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr

Psychiatry. 2002;43:393–6. Article  PubMed  Google Scholar  * Brower KJ. Insomnia, alcoholism and relapse. Sleep Med Rev. 2003;7:523–39. Article  PubMed  Google Scholar  * Suchting R, Yoon

JH, Miguel GGS, Green CE, Weaver MF, Vincent JN, et al. Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Res. 2020;1731:146359. Article

  PubMed  CAS  Google Scholar  * Krystal AD, Goforth HW, Roth T. Effects of antipsychotic medications on sleep in schizophrenia. Int Clin Psychopharmacol 2008;23:150–60. Article  PubMed 

Google Scholar  * Monti JM, Torterolo P, Pandi Perumal SR. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep

Med Rev. 2017;33:51–7. Article  PubMed  Google Scholar  * Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients

with chronic schizophrenia. N. Engl J Med. 2005;353:1209–23. Article  PubMed  CAS  Google Scholar  * McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH, et al.

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31:180–6. Article  PubMed  PubMed Central  Google

Scholar  * American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013. * American Academy of Sleep

Medicine, International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014. * Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ,

Lichstein KL, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med.

2021;17:255–62. Article  PubMed  PubMed Central  Google Scholar  * Riemann D, Espie CA, Altena E, Arnardottir ES, Baglioni C, Bassetti CLA, et al. The European Insomnia Guideline: an update

on the diagnosis and treatment of insomnia 2023. J Sleep Res. 2023;32:e14035. Article  PubMed  Google Scholar  * Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline

for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487–504. Article  PubMed  PubMed Central  Google Scholar  * Hertenstein E, Trinca E, Wunderlin M,

Schneider CL, Züst MA, Fehér KD, et al. Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis. Sleep Med

Rev. 2022;62:101597. Article  PubMed  Google Scholar  * Miller CB, Espie CA, Bartlett DJ, Marshall NS, Gordon CJ, Grunstein RR. Acceptability, tolerability, and potential efficacy of

cognitive behavioural therapy for insomnia disorder subtypes defined by polysomnography: a retrospective cohort study. Sci Rep. 2018;8:6664. Article  PubMed  PubMed Central  Google Scholar 

* Bathgate CJ, Edinger JD, Krystal AD. Insomnia patients with objective short sleep duration have a blunted response to cognitive behavioral therapy for insomnia. Sleep. 2017;40:zsw012.

PubMed  Google Scholar  * Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American

Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13:307–49. Article  PubMed  PubMed Central  Google Scholar  * Okuda S, Qureshi ZP, Yanagida Y, Ito C, Homma Y,

Tokita S. Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database. BMC Psychiatry. 2023;23:278. Article  PubMed 

PubMed Central  CAS  Google Scholar  * Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, et al. Improved insomnia symptoms and sleep-related next-day functioning in

patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin

Psychiatry. 2011;72:914–28. Article  PubMed  CAS  Google Scholar  * Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, et al. A post hoc analysis of the effect of nightly

administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011;72:473–9. Article  PubMed  CAS  Google

Scholar  * Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.

Biol Psychiatry. 2006;59:1052–60. Article  PubMed  CAS  Google Scholar  * Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci.

2011;34:188–97. Article  PubMed  PubMed Central  CAS  Google Scholar  * Han Y, Yuan K, Zheng Y, Lu L. Orexin receptor antagonists as emerging treatments for psychiatric disorders. Neurosci

Bull 2020;36:432–48. Article  PubMed  CAS  Google Scholar  * Janssen Research & Development, LLC. A study of seltorexant as adjunctive therapy to antidepressants in adult and elderly

participants with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant and long-term safety extension treatment with seltorexant.

ClinicalTrials.gov identifier: NCT04533529. Updated March 2, 2023. https://clinicaltrials.gov/ct2/show/NCT04533529. Accessed 12 Apr 2023. * Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar

D, Dhadda S, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical

trial. JAMA Netw Open. 2019;2:e1918254. Article  PubMed  PubMed Central  Google Scholar  * Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, et al. Suvorexant in patients with

insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79:136–48. Article  PubMed  CAS  Google Scholar  * Culpepper L, Krystal A, Pinner K, Moline M.

Post hoc analysis of the impact of lemborexant on patient-reported sleep and insomnia severity in adults with insomnia and depression histories. CNS Spectr. 2022;27:243. Article  Google

Scholar  * Kishi T, Nomura I, Matsuda Y, Sakuma K, Okuya M, Ikuta T, et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res.

2020;128:68–74. Article  PubMed  Google Scholar  * Matsuoka A, Sogawa R, Murakawa-Hirachi T, Shinada K, Murakawa-Hirachi T, Shimanoe C, et al. Evaluation of the delirium preventive effect of

dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: a single-center, retrospective,

observational study. Gen. Hosp. Psychiatry. 2023. https://doi.org/10.1016/j.genhosppsych.2023.03.010. * Mellman TA, Birku K, Sandhu I, Lavela P, Kobayashi I. Evaluation of suvorexant for

trauma-related insomnia. Sleep. 2022;45:zsac068. Article  PubMed  Google Scholar  * Wang PW Efficacy of suvorexant to treat insomnia related to bipolar disorder. ClinicalTrials.gov

identifier: NCT02527564. Updated October 6, 2022. https://clinicaltrials.gov/ct2/show/NCT02527564. Accessed 12 Apr 2023. * Shigetsura Y, Imai S, Endo H, Shimizu Y, Ueda K, Murai T, et al.

Assessment of suvorexant and eszopiclone as alternatives to benzodiazepines for treating insomnia in patients with major depressive disorder. Clin Neuropharmacol 2022;45:52–60. PubMed  CAS 

Google Scholar  * Izuhara M, Miura S, Otsuki K, Nagahama M, Hayashida M, Hashioka S, et al. Magnetic resonance spectroscopy in the ventral tegmental area distinguishes responders to

suvorexant prior to treatment: a 4-week prospective cohort study. Front Psychiatry. 2021;12:714376. Article  PubMed  PubMed Central  Google Scholar  * Kishi T, Sakuma K, Okuya M, Ninomiya K,

Oya K, Kubo M, et al. Suvorexant for insomnia in patients with psychiatric disorder: a 1-week, open-label study. Neuropsychopharmacol Rep. 2019;39:252–5. Article  PubMed  PubMed Central 

CAS  Google Scholar  * Nakamura M, Nagamine T. Neuroendocrine, autonomic, and metabolic responses to an orexin antagonist, suvorexant, in psychiatric patients with insomnia. Innov Clin

Neurosci. 2017;14:30–7. PubMed  PubMed Central  Google Scholar  * Kishi T, Sakuma K, Okuya M, Iwata N. Lemborexant for insomnia in adults with psychiatric disorders: a 1-week, open-label

study. Psychiatry Clin Neurosci Rep. 2022;1:e23. Google Scholar  * Kawabe K, Horiuchi F, Ochi M, Nishimoto K, Ueno SI, Oka Y. Suvorexant for the treatment of insomnia in adolescents. J Child

Adolesc Psychopharmacol 2017;27:792–5. Article  PubMed  CAS  Google Scholar  * Murata T. Quetiapine may complete the best match with suvorexant in psychiatric patients with insomnia. Int J

Clin Pharmacol Ther 2021;59:341–2. Article  PubMed  Google Scholar  * Suzuki H, Hibino H. The effect of lemborexant for insomnia disorder. SAGE Open Med. 2021;9.

https://doi.org/10.1177/20503121211039098. * Katsuta N, Takahashi K, Kurosawa Y, Yoshikawa A, Takeshita Y, Uchida Y, et al. Safety and real-world efficacy of lemborexant in the treatment of

comorbid insomnia. Sleep Med. 2023;5:100070. Google Scholar  * Asai Y, Sano H, Miyazaki M, Iwakura M, Maeda Y, Hara M. Suvorexant (Belsomra® tablets 10, 15, and 20 mg): Japanese drug-use

results survey. Drugs R D 2019;19:27–46. Article  PubMed  CAS  Google Scholar  * Hatano M, Kamei H, Inagaki R, Matsuzaki H, Hanya M, Yamada S, et al. Assessment of switching to suvorexant

versus the use of add-on suvorexant in combination with benzodiazepine receptor agonists in insomnia patients: a retrospective study. Clin Psychopharmacol Neurosci 2018;16:184–9. Article 

PubMed  PubMed Central  CAS  Google Scholar  * Truong TT. Lemborexant augmentation of naltrexone for alcohol craving and sleep. ClinicalTrials.gov identifier: NCT05458609. Updated February

10, 2023. https://clinicaltrials.gov/ct2/show/NCT05458609. Accessed 12 Apr 2023 * The Florey Institute of Neuroscience and Mental Health. Suvorexant in the management comorbid sleep disorder

and alcohol dependence. ClinicalTrials.gov identifier: NCT03897062. Updated February 15, 2023. https://clinicaltrials.gov/ct2/show/NCT03897062. Accessed 12 Apr 2023. * J Hopkins University.

Examining the role of the orexin system in sleep and stress in persons with opioid use disorder. ClinicalTrials.gov identifier: NCT04287062. Updated May 20, 2022.

https://clinicaltrials.gov/ct2/show/NCT04287062. Accessed 12 Apr 2023. * Bunce SC. The efficacy of suvorexant in treatment of patients with substance use disorder and insomnia: a pilot open

trial (Suvsubuse). ClinicalTrials.gov identifier: NCT03412591. Updated February 27, 2023. https://clinicaltrials.gov/ct2/show/NCT03412591. Accessed 12 Apr 2023. * VA Office of Research and

Development. Suvorexant: a dual orexin receptor antagonist for treating sleep disturbance in posttraumatic stress. ClinicalTrials.gov identifier: NCT03642028. Updated November 14, 2022.

https://clinicaltrials.gov/ct2/show/NCT03642028. Accessed 12 Apr 2023. * Commonwealth V. University. Drug-drug interaction study of lemborexant as an adjunctive treatment for

buprenorphine/naloxone for opioid use disorder. ClinicalTrials.gov identifier: NCT04818086. Updated March 20, 2023. https://clinicaltrials.gov/ct2/show/NCT04818086. Accessed April 12, 2023 *

Institute for Advanced Medical Research, Alpharetta, GA. A six week, randomized, double-blind placebo-controlled, suvorexant augmentation study of antidepressant treatment of major

depressive disorder with residual insomnia. ClinicalTrials.gov identifier: NCT02669030. Updated February 27, 2019. https://clinicaltrials.gov/ct2/show/NCT02669030. Accessed 12 Apr 2023. *

James MH, Aston-Jones G. Orexin reserve: a mechanistic framework for the role of orexins (hypocretins) in addiction. Biol Psychiatry. 2022;92:836–44. Article  PubMed  PubMed Central  CAS 

Google Scholar  * Palagini L, Geoffroy PA, Alfi G, Annuzzi E, Gurrieri R, Caruso V, et al. Insomnia and the orexinergic pathway in the link with psychopathology: effects of DORAs in insomnia

comorbid with mental disturbances. Curr. Sleep Med. Rep. 2024. https://doi.org/10.1007/s40675-024-00294-9. * Fragale JE, James MH, Avila JA, Spaeth AM, Aurora RN, Langleben D, et al. The

insomnia-addiction positive feedback loop: role of the orexin system. Front Neurol Neurosci 2021;45:117–27. Article  PubMed  PubMed Central  Google Scholar  * Gorka SM. Orexin receptor

antagonists as modulators of threat sensitivity in individuals with alcohol use disorder. ClinicalTrials.gov identifier: NCT05656534. Updated December 19, 2022.

https://clinicaltrials.gov/ct2/show/NCT05656534. Accessed 12 Apr 2023 * J Hopkins University. Suvorexant for opioid/stimulant co-use. ClinicalTrials.gov identifier: NCT05546515. Updated

December 15, 2022. https://clinicaltrials.gov/ct2/show/NCT05546515. Accessed 12 Apr 2023. * Suchting R Suvorexant to reduce symptoms of nicotine use. ClinicalTrials.gov identifier:

NCT04234997. Updated February 16, 2023. https://clinicaltrials.gov/ct2/show/NCT04234997. Accessed 12 Apr 2023. * Janes AC Targeting orexin to treat nicotine dependence. ClinicalTrials.gov

identifier: NCT03999099. Updated August 31, 2021. https://clinicaltrials.gov/ct2/show/NCT03999099. Accessed 12 Apr 2023. * Murakoshi A, Takaesu Y, Komada Y, Ishikawa J, Inoue Y. Prevalence

and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders. Psychiatry Res. 2015;230:958–63. Article  PubMed  Google Scholar  * Michelson D, Snyder

E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase

3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461–71. Article  PubMed  CAS  Google Scholar  * Takaesu Y, Suzuki M, Moline M, Pinner K, Inabe K, Nishi Y, et al.

Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: secondary analysis of a randomized clinical trial. Clin Transl Sci. 2023;16:581–92. Article 

PubMed  PubMed Central  CAS  Google Scholar  * Okada I, Miyata S, Iwamoto K, Fujishiro H, Noda A, Ozaki N. Prevalence of obstructive sleep apnea as assessed by polysomnography in psychiatric

patients with sleep-related problems. Sleep Breath. 2022;26:1983–91. Article  PubMed  Google Scholar  * Leucht S, Schneider-Thoma J, Burschinski A, Peter N, Wang D, Dong S, et al. Long-term

efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. World Psychiatry. 2023;22:315–24. Article  PubMed  PubMed

Central  Google Scholar  * Schneider-Thoma J, Chalkou K, Dörries C, Bighelli I, Ceraso A, Huhn M, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable

antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399:824–36. Article  PubMed  CAS  Google Scholar  *

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with

multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–51. Article  PubMed  PubMed Central  CAS  Google Scholar  * Kishi T, Ikuta T, Sakuma K, Okuya

M, Iwata N. Efficacy and safety of antipsychotic treatments for schizophrenia: a systematic review and network meta-analysis of randomized trials in Japan. J Psychiatr Res. 2021;138:444–52.

Article  PubMed  Google Scholar  * Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults

with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43:zsaa123. Article  PubMed  PubMed Central  Google Scholar  * Ahmad M, Kelly J, Montano CB,

Kumar D, Perdomo C, Malhotra M, et al. Transitioning insomnia patients from zolpidem to lemborexant: a multicenter, open-label study evaluating a next-dose transition approach to insomnia

pharmacotherapy. Sleep Med X. 2023;7:100098. Article  PubMed  PubMed Central  Google Scholar  * Ozone M, Hirota S, Ariyoshi Y, Hayashida K, Ikegami A, Habukawa M, et al. Efficacy and safety

of transitioning to lemborexant from Z-drug, suvorexant, and ramelteon in Japanese insomnia patients: an open-label, multicenter study. Adv Ther. 2015;41:1728–45. Article  Google Scholar 

Download references ACKNOWLEDGEMENTS The authors wish to thank Katherine Halievski, PhD, of Edanz (www.edanz.com), and Infront Medical Publications for providing medical writing support,

which was funded by Eisai Co., Ltd, in accordance with the 2022 Good Publication Practice guidelines (https://www.ismpp.org/gpp-2022). FUNDING Eisai Co., Ltd, supported the present work by

funding the medical writing support and the publication fees. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Psychiatry, Fujita Health University School of Medicine, Toyoake,

Aichi, Japan Taro Kishi & Nakao Iwata * Medical Headquarters, Eisai Co, Ltd, Tokyo, Japan Michinori Koebis, Michiko Sugawara, Yuka Kawatsu & Takehiro Taninaga Authors * Taro Kishi

View author publications You can also search for this author inPubMed Google Scholar * Michinori Koebis View author publications You can also search for this author inPubMed Google Scholar *

Michiko Sugawara View author publications You can also search for this author inPubMed Google Scholar * Yuka Kawatsu View author publications You can also search for this author inPubMed 

Google Scholar * Takehiro Taninaga View author publications You can also search for this author inPubMed Google Scholar * Nakao Iwata View author publications You can also search for this

author inPubMed Google Scholar CONTRIBUTIONS TK and TT conceived the review; MK and YK conducted the systematic literature search; and MK and MS drafted the manuscript. All authors reviewed

and approved the final version of the manuscript. CORRESPONDING AUTHORS Correspondence to Taro Kishi or Michinori Koebis. ETHICS DECLARATIONS COMPETING INTERESTS TK has received speaker’s

honoraria from Eisai Co., Ltd, Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd, Mitsubishi

Tanabe Pharma Corporation, KYOWA Pharmaceutical Industry Co., Ltd, Yoshitomiyakuhin Corporation, and Viatris, and research grants from Eisai Co., Ltd, Grants-in-Aid for Scientific Research

(C) (19K08082 and 23K06998), Japan Agency for Medical Research and Development (JP22dk0307107, JP22wm0525024, JP23dk0307122 and 24dk0307129), and the Japanese Ministry of Health, Labour and

Welfare (21GC1018). MK, MS, YK, and TT are employees of Eisai Co., Ltd. NI has received speaker’s honoraria from Eisai Co., Ltd, Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd,

Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, and Viatris Inc., and research grants from Daiichi Sankyo Co.,

Ltd, Eisai Co., Ltd, Meiji Seika Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd, and Mitsubishi Tanabe Pharma Corporation.

ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION

SUPPORTING INFORMATION RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,

distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and

indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to

the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE

CITE THIS ARTICLE Kishi, T., Koebis, M., Sugawara, M. _et al._ Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review. _Transl

Psychiatry_ 14, 374 (2024). https://doi.org/10.1038/s41398-024-03087-4 Download citation * Received: 19 September 2023 * Revised: 02 September 2024 * Accepted: 02 September 2024 * Published:

14 September 2024 * DOI: https://doi.org/10.1038/s41398-024-03087-4 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry,

a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative